Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Prevention of Blindness: Trachoma Control

Trachoma is estimated to affect approximately 500 million people, primarily in rural communities of the developing world and in the arid areas of tropical and subtropical zones. Approximately 6-9 million* people are blind from trachoma, and many more have suffered partial loss of vision.

Trachoma can be controlled, and blindness and visual loss can be prevented by appropriate application of relatively simple and inexpensive measures. Therefore, communities with uncontrolled trachoma should be identified so that appropriate control measures can be implemented. Such communities are likely to be found in countries where blindness rates are above the range of 0.5%-1%, and where more than 1%-2% of the population are blind from all causes.

In recent years, preventable and easily curable blindness has been recognized as a combatible public health problem. The need for blindness prevention has led to a renewed interest in trachoma and associated infections, which are still the most important causes of preventable blindness in the world.

In 1975, the Twenty-Eighth World Health Assembly, in a resolution on the prevention of blindness, requested the Director General of the World Health Organization "to encourage member countries to develop national programmes for the prevention of blindness, especially aimed at the control of trachoma, xerophthalmia, onchocerciasis, and other causes, and to introduce adequate measures for the early detection and treatment for other potentially blinding conditions such as cataract and glaucoma."

Trachoma-control programs must be aimed primarily at those severely affected communities where the disease leads to blindness. In planning and implementing control programs, consideration must be given to the simultaneous introduction of other specific measures for dealing with all causes of avoidable blindness. In recent years, knowledge about the causative agent of trachoma and about the epidemiologic patterns that determine the intensity of inflammation and the gravity of disease has increased substantially. This new information has led to a clearer definition of risk for the individual and for the community and has made it possible to distinguish communities with "blinding trachoma" from those with "non-blinding trachoma." In view of these developments and the importance of trachoma control in the prevention of blindness, a revised guide to trachoma control has been prepared (1).

This new field guide presents simple and effective methods suitable for widespread implementation in underserved communities with blinding trachoma. It stresses the importance of maximum participation of the people themselves in promotion of health care for the prevention and cure of blinding trachoma. This approach makes the best possible use of available but limited resources and is in accord with the defined health objectives and reorientation of health activities found in the Declaration of Alma-Ata on Primary Health Care.

The guide also outlines basic principles for the organization of trachoma-control programs. It summarizes present knowledge on the epidemiologic and clinical aspects of the disease, explains the most commonly used approach of large-scale trachoma treatment through control of infection transmission, and describes the more intensive treatment of individual cases. It also contains recommendations on training activities, health education, evaluation of results, and monitoring of programs. The basic methods described can be suitably adapted to local conditions and should allow the swift and effective implementation of trachoma-control programs. Reported by WHO Weekly Epidemiological Record 1982;57:189-90.


  1. World Health Organization. Guide to trachoma control. Geneva: World Health Organization 1981. *Estimate endorsed by the WHO Programme Advisory Group on the Prevention of Blindness in February 1982.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.

All MMWR HTML versions of articles are electronic conversions from typeset documents. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version ( and/or the original MMWR paper copy for printable versions of official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.

**Questions or messages regarding errors in formatting should be addressed to The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO
A-Z Index
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  27. #